Related references
Note: Only part of the references are listed.Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma
Adam J. Olszewski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Preetesh Jain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States
Shaum M. Kabadi et al.
CANCER MEDICINE (2019)
Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States
Ravi K. Goyal et al.
LEUKEMIA & LYMPHOMA (2019)
Frontline Treatment for Older Patients with Mantle Cell Lymphoma
Haige Ye et al.
ONCOLOGIST (2018)
Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas
Shuangshuang Fu et al.
ONCOTARGET (2017)
Bendamustine-rituximab in mantle cell lymphoma
Andrew Lipsky et al.
LANCET HAEMATOLOGY (2017)
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Mathias Rummel et al.
LANCET ONCOLOGY (2016)
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data
Mark D. Danese et al.
MEDICAL CARE (2016)
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
C. Y. Cheah et al.
ANNALS OF ONCOLOGY (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients
Janice Y. Chyou et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn et al.
BLOOD (2014)
Healthcare resource utilization (HRU) in treated mantle cell lymphoma (MCL) patients
Chris M. Kozma et al.
CANCER RESEARCH (2014)
Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting
Sara Hurvitz et al.
ONCOLOGIST (2014)
Comparative Effectiveness and Cost of Adding Rituximab to First-Line Chemotherapy for Elderly Patients Diagnosed With Diffuse Large B-Cell Lymphoma
Robert I. Griffiths et al.
CANCER (2012)
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
Robert Griffiths et al.
BLOOD (2011)
The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients
Mary E. Charlson et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Share Paper
